Dermapharm grows thanks to Arkopharma and nutritional supplements
Business at pharmaceutical manufacturer Dermapharm is still flourishing after nine months. In the first three quarters, the company benefited from its subsidiary Arkopharma and increased demand for dietary supplements and herbal extracts. This enabled the Group to cushion the impact of the discontinuation of vaccine production for Biontech. According to Group figures released on Wednesday, turnover from January to September rose by 18 percent year-on-year to just under 867 million euros.
Because two areas of the Group are struggling with declining earnings, earnings before interest, taxes, depreciation and amortization (adjusted EBITDA) climbed comparatively slightly by just under two percent to around 244 million euros.
The increase in demand for dietary supplements and herbal extracts, primarily driven by Arkopharma, significantly contributed to Dermapharm's successful performance in the first three quarters. Moreover, the pharmaceutical company's quarterly figures reveal a 18% rise in turnover, reaching nearly 867 million euros, due to the combined impact of Arkopharma and the booming medicine market.
Source: www.dpa.com
